Greater Cannabis Partners with Shaare Zedek Scientific on Innovative Neuropsychiatric Cannabinoid Therapy

Photo by Ousa Chea on Unsplash

Greater Cannabis Company, Inc. (OTCQB: GCAN), a pioneer of cannabinoid pharmaceuticals and consumer products, has recently signed a licensing agreement with Shaare Zedek Scientific Ltd (SZS), the research and development subsidiary of Shaare Zedek Center.

Greater Cannabis Company, Inc. is a Baltimore-based biopharmaceutical company specializing in developing and commercializing innovative cannabinoid therapeutics and consumer products. 

This latest partnership between Greater Cannabis and Shaare Zedek Scientific represents a critical step for ongoing clinical research of cannabinoid therapeutics in the field of pediatric neurology, as well as consumer product development. The agreement covers the license of SZS’s novel cannabinoid therapeutics geared toward the treatment of various neuropsychiatric disorders, including autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

Alongside the …

Full story available on Benzinga.com

More Greater Cannabis Partners with Shaare Zedek Scientific on Innovative Neuropsychiatric Cannabinoid Therapy